Once-Daily Asthma Inhaler Approved
Posted on: Friday, 1 April 2005, 12:00 CST
FRIDAY, April 1 (HealthDay News) -- The U.S. Food and Drug Administration has approved Schering-Plough's once-daily asthma inhaler Asmanex (mometasone furoate).
The dry-powder preventive therapy is sanctioned for asthmatics 12 and older who had been treated with oral medications called bronchodilators or inhaled corticosteroids, the company said in a statement.
The active ingredient is the same one used in Schering-Plough's Nasonex, a nasal allergy spray.
In clinical trials involving 400 people, participants who used Asmanex showed improved lung function, less reliance on short-term "rescue" asthma medications, and significant improvement in day and nighttime symptoms such as coughing and wheezing, the company said.
As many as 20 million Americans have asthma, leading to 2 million emergency room visits and more than 5,000 deaths annually, Schering-Plough said.
To learn more about asthma, visit the National Heart, Lung, and Blood Insitute.
~ASTH~~FDA-~
Source: HealthSCOUT
Related Articles
- Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
- Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
- Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
- Schering-Plough Announces Imperfect Contraceptive Use Impacts Women's Emotional Well-Being
- Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
- Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status By U.S. FDA
- Schering-Plough Announces Asenapine NDA Accepted for Filing By the U.S. FDA
- Novacea and Schering-Plough Enter Into Worldwide Development and Commercialization Agreement for Asentar, a Novel Treatment for Prostate Cancer
- Schering-Plough and OraSure Technologies Sign Agreement for Development and Promotion of Rapid Point-Of-Care Oral Hepatitis C Test
- Schering-Plough to Acquire From Millennium Exclusive U.S. Marketing Rights for INTEGRILIN(R) (Eptifibatide) Injection
 |
 |
User Comments (0)
RSS Feeds